Is Buying Aptevo Therapeutics Inc (NASDAQ:APVO), Having Lower Short Interest a Winning Strategy?

September 16, 2018 - By Richard Doty

The stock of Aptevo Therapeutics Inc (NASDAQ:APVO) registered a decrease of 9.18% in short interest. APVO’s total short interest was 191,900 shares in September as published by FINRA. Its down 9.18% from 211,300 shares, reported previously. With 89,000 shares average volume, it will take short sellers 2 days to cover their APVO’s short positions. The short interest to Aptevo Therapeutics Inc’s float is 1.16%.

The stock increased 0.99% or $0.05 during the last trading session, reaching $5.08. About 22,160 shares traded. Aptevo Therapeutics Inc. (NASDAQ:APVO) has risen 188.14% since September 16, 2017 and is uptrending. It has outperformed by 172.52% the S&P500.

Aptevo Therapeutics Inc., a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. The company has market cap of $115.16 million. The Company’s marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn. It has a 101.6 P/E ratio. The companyÂ’s marketed products also comprise HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B; and VARIZIG for use in treating following exposure to varicella zoster virus, which causes chickenpox in high-risk individuals.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.